#United States #New York #Class Action #Gross Law Firm #BioAge Labs

Important Reminder for BioAge Labs, Inc. Shareholders

Investors in BioAge Labs, Inc. are being urged by The Gross Law Firm to take action before March 10, 2025, regarding their investment rights. The law firm's announcement comes as a notification for shareholders who acquired shares in BioAge Labs (NASDAQ: BIOA) during a specific class period. This notice highlights the importance of understanding potential legal actions and their implications for current and former shareholders.

Background on BioAge Labs, Inc.

BioAge Labs is a biotechnology company focusing on prolonging life and improving health transparency through medical technologies. On December 6, 2024, the company announced the discontinuation of its STRIDES Phase 2 trial for azelaprag, its flagship product. This unexpected announcement pointed to safety concerns regarding elevated liver transaminase levels among trial participants.

The Impact of the Discontinuation

When BioAge revealed that it would halt its ongoing phase 2 trials, financial repercussions quickly followed. The company's stock price plummeted from $20.09 per share on December 6, 2024, to just $4.65 on December 7, 2024. Shareholders were shocked by this sudden decline, prompting many to seek legal counsel as they consider their options in light of these developments.

Legal Actions Available for Investors

Shareholders who purchased BioAge stock during the relevant time period are encouraged to contact The Gross Law Firm for advice regarding the possible appointment as lead plaintiff in a class action lawsuit. It is crucial for affected investors to understand that registration is necessary to participate in the potential recovery of losses, but appointment as lead plaintiff is not a prerequisite.

Steps for Interested Shareholders

1. Register Your Information: It’s vital for shareholders who wish to be part of this class action to register online through the specified link by March 10, 2025.
2. Portfolio Monitoring: After registration, participants will gain access to a portfolio monitoring system that will keep them informed about the status of the case and any critical updates as they arise.

The Gross Law Firm emphasizes that this process does not incur any costs or obligations for those who decide to participate, making it essential for affected shareholders to register promptly.

The Role of The Gross Law Firm

The Gross Law Firm is recognized for its dedication to protecting investors’ rights. With its broad range of experience in dealing with class action lawsuits, the firm aims to recover losses for shareholders impacted by corporate deceit and ambiguity in reporting. They are committed to ensuring that investor rights are upheld in all circumstances.

For shareholders who feel misled or harmed due to BioAge's announcements, reaching out to The Gross Law Firm can guide them through their options and help secure potential compensatory remedies.

Deadline Reminder

Keep in mind that the last day to register for the class action lawsuit is March 10, 2025. Shareholders are encouraged not to delay in taking action as time is of the essence in these legal situations.

For further inquiries or to begin the registration process, interested parties can reach The Gross Law Firm via the provided contact details. Protecting your investment and rights is paramount, and timely action is crucial.

Contact Information

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Investors are reminded that understanding your rights and the avenues available for potential recovery is vital in navigating the fallout from this recent development concerning BioAge Labs.